Clinical trials have demonstrated that SGLT2i drugs such as empagliflozin, canagliflozin, and GLP-1 receptor agonists reduce the risk of cardiovascular adverse events, and Dapagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure [5, 29]. This evidence concerns the gene GLP1R and heart failure.